Study #2024-1548
REJOICE-pantumor01: a phase 2, multicenter, open-label, pan-tumor trial to evaluate efficacy and safety of Raludotatug deruxtecan (R-DXd) in participants with advanced/metastatic solid tumors
MD Anderson Study Status
Enrolling
Treatment Agent
Raludotatug deruxtecan
Description
This pan-tumor trial is designed as a signal-seeking trial to assess efficacy and safety of raludotatug deruxtecan (R-DXd) monotherapy in locally advanced or metastatic solid tumors with various cadherin-6 (CDH6) expression levels, including gynecological cancers (endometrial cancer, cervical cancer, and non-high-grade serous ovarian cancer) and genitourinary cancers (urothelial cancer and clear cell renal cell carcinoma \[ccRCC\]).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Advanced Solid Tumor, Metastatic Solid Tumors
Study phase:
Phase II
Physician name:
Sarina Piha-Paul
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-866-967-2182
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.